Acute Pancreatitis

Chris E. Forsmark, M.D., Santhi Swaroop Vege, M.D., and C. Mel Wilcox, M.D.

The incidence of acute pancreatitis is increasing in the United States, and the disorder is now one of the most common reasons for hospitalization with a gastrointestinal condition. In this review, we consider recent changes in the management of acute pancreatitis, as well as common misunderstandings and areas of ongoing controversy.

Causes of Acute Pancreatitis

Table 1 lists the causes of acute pancreatitis. Gallstones are the most common cause.1,2 Migrating gallstones cause transient obstruction of the pancreatic duct, a mechanism shared by other recognized causes (e.g., endoscopic retrograde cholangiopancreatography [ERCP]), as well as purported causes (i.e., pancreas divisum and sphincter of Oddi dysfunction). A recent trial failed to show that sphincter of Oddi dysfunction contributed to post-cholecystectomy biliary pain,3 and there are no convincing data from controlled trials that either pancreatic sphincter of Oddi dysfunction or pancreas divisum plays a role in acute pancreatitis.4-6

Alcohol is the second most common cause of acute pancreatitis. Prolonged alcohol use (four to five drinks daily over a period of more than 5 years) is required for alcohol-associated pancreatitis;7 the overall lifetime risk of pancreatitis among heavy drinkers is 2 to 5%. In most cases, chronic pancreatitis has already developed and the acute clinical presentation represents a flare superimposed on chronic pancreatitis. The risk is higher for men than for women, perhaps reflecting differences in alcohol intake or genetic background.8 The mechanisms by which alcohol causes acute (or chronic) pancreatitis are complex and include both direct toxicity and immunologic mechanisms.9 The type of alcohol ingested does not affect risk, and binge drinking in the absence of long-term, heavy alcohol use does not appear to precipitate acute pancreatitis.10

Drugs appear to cause less than 5% of all cases of acute pancreatitis, although hundreds of drugs have been implicated.11 The drugs most strongly associated with the disorder are azathioprine, 6-mercaptopurine, didanosine, valproic acid, angiotensin-converting–enzyme inhibitors, and mesalamine. Pancreatitis caused by drugs is usually mild. Recent data do not support a role for glucagon-like peptide 1 mimetics in causing pancreatitis.12 It is common for patients to be taking one of the many drugs associated with pancreatitis when they are admitted to the hospital with acute pancreatitis,13 but it is exceedingly difficult to determine whether the drug is responsible.

Mutations and polymorphisms in a number of genes are associated with acute (and chronic) pancreatitis, including mutations in the genes encoding cationic trypsinogen (PRSS1), serine protease inhibitor Kazal type 1 (SPINK1), cystic fibrosis transmembrane conductance regulator (CFTR), chymotrypsin C, calcium-sensing receptor, and claudin-2.14 These mutations may serve as cofactors, interacting with...
Table 1. Causes of Acute Pancreatitis.*

<table>
<thead>
<tr>
<th>Cause</th>
<th>Approximate Frequency</th>
<th>Diagnostic Clues</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gallstones</td>
<td>40%</td>
<td>Gallbladder stones or sludge, abnormal liver-enzyme levels</td>
<td>Endoscopic ultrasonography can reveal very small gallbladder or duct stones.</td>
</tr>
<tr>
<td>Alcohol</td>
<td>30%</td>
<td>Acute flares superimposed on underlying chronic pancreatitis</td>
<td>Diagnosis rests on history, obtained with CAGE questions.†</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>2–5%</td>
<td>Fasting triglycerides &gt;1000 mg/dl (11.3 mmol per liter)</td>
<td></td>
</tr>
<tr>
<td>Genetic causes</td>
<td>Not known</td>
<td>Recurrent acute pancreatitis and chronic pancreatitis</td>
<td></td>
</tr>
<tr>
<td>Drugs</td>
<td>&lt;5%</td>
<td>Other evidence of drug allergy (e.g., rash) only in rare cases</td>
<td>The condition is idiosyncratic and usually mild.</td>
</tr>
<tr>
<td>Autoimmune cause</td>
<td>&lt;1%</td>
<td>Type 1: obstructive jaundice, elevated serum IgG4 levels, response to glucocorticoids; type 2: possible presentation as acute pancreatitis; occurrence in younger patients; no IgG4 elevation; response to glucocorticoids</td>
<td>Type 1 is a systemic disease affecting the pancreas, salivary glands, and kidneys; in type 2, only the pancreas is affected.</td>
</tr>
<tr>
<td>ERCP</td>
<td>5–10% (among patients undergoing ERCP)</td>
<td></td>
<td>The symptoms can be reduced with rectal NSAIDS (diclofenac or indomethacin) or temporary placement of a stent in the pancreatic duct.</td>
</tr>
<tr>
<td>Trauma</td>
<td>&lt;1%</td>
<td>Blunt or penetrating trauma, particularly in midbody of pancreas as it crosses spine</td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>&lt;1%</td>
<td>Viruses: CMV, mumps, and EBV most common; parasites: ascaris and clonorchis</td>
<td></td>
</tr>
<tr>
<td>Surgical complication</td>
<td>5–10% (among patients undergoing cardiopulmonary bypass)</td>
<td>The condition is probably due to pancreatic ischemia; pancreatitis may be severe.</td>
<td></td>
</tr>
<tr>
<td>Obstruction</td>
<td>Rare</td>
<td>Celiac disease and Crohn’s disease, pancreas divisum (controversial), and sphincter of Oddi dysfunction (very controversial)</td>
<td>On rare occasions, malignant pancreatic duct or ampullary obstruction is seen.</td>
</tr>
<tr>
<td>Associated conditions</td>
<td>Common</td>
<td>Diabetes, obesity, and smoking</td>
<td></td>
</tr>
</tbody>
</table>

* CMV denotes cytomegalovirus, EBV Epstein–Barr virus, ERCP endoscopic retrograde cholangiopancreatography, and NSAIDS nonsteroidal antiinflammatory drugs.
† CAGE is an acronym for the following questions: Have you ever felt you should cut down on your drinking? Have people annoyed you by criticizing your drinking? Have you ever felt bad or guilty about your drinking? Have you ever had a drink first thing in the morning to steady your nerves or to get rid of a hangover (eye opener)?
other causes; for example, claudin-2 mutations work synergistically with alcohol.8,14

The cause of acute pancreatitis often cannot be established, and the proportion of persons who are considered to have idiopathic acute pancreatitis increases with age. A number of potential factors might contribute to unexplained pancreatitis, including unidentified genetic polymorphisms, exposure to smoking and other environmental toxins, and effects of coexisting diseases that are commonly associated with acute pancreatitis (e.g., obesity and diabetes). Morbid obesity is a risk factor for acute pancreatitis2,16 and for severe acute pancreatitis.17 Type 2 diabetes increases the risk of acute pancreatitis by a factor of 2 or 3.2 Both obesity and diabetes are also risk factors for chronic pancreatitis and pancreatic cancer.18

**Epidemiology**

Acute pancreatitis in the United States accounts for health care costs of $2.5 billion19 and for 275,000 admissions each year. Admissions have increased by at least 20% over the past 10 years. Studies worldwide have shown a rising but variable incidence of acute pancreatitis, including large increases in incidence in pediatric populations.20 This increased risk of pancreatitis tracks with the worldwide obesity epidemic and increasing rates of gallstones. Approximately 80% of patients admitted with acute pancreatitis have mild, self-limited disease and are discharged within several days. Mortality associated with acute pancreatitis has decreased over time, and the overall mortality is now approximately 2%. Death is more likely in certain subgroups of patients, including the elderly, those with more numerous and more severe coexisting conditions (particularly obesity), those in whom hospital-acquired infections develop, and those with severe episodes of acute pancreatitis (characterized by persistent failure of one or more organ systems or infected pancreatic necrosis).

**Diagnosis and Classification**

Accurate diagnosis of acute pancreatitis requires at least two of the following three diagnostic features21: abdominal pain consistent with acute pancreatitis, serum lipase or amylase levels that are at least 3 times the upper limit of the normal range, and findings of acute pancreatitis on cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging). Patients with vague abdominal symptoms and a minimally increased serum amylase or lipase level should not receive a diagnosis of acute (or chronic) pancreatitis. Cross-sectional imaging is invaluable in confirming an initial diagnostic impression, in assessing patients for other conditions that might mimic acute pancreatitis, and in evaluating patients with atypical symptoms or small elevations in serum pancreatic enzyme levels.

According to a recent international consensus (see the Supplementary Appendix, available with the full text of this article at NEJM.org), the classifications of moderately severe pancreatitis and severe pancreatitis are defined by the presence of complications that are systemic, local, or both. Systemic complications include failure of an organ system (respiratory, cardiovascular, or renal) and exacerbation of a preexisting disorder (e.g., chronic obstructive pulmonary disease, heart failure, or chronic liver disease). Local complications comprise peripancreatic fluid collections or pseudocysts and pancreatic or peripancreatic necrosis, whether sterile or infected. In this classification system, persistent failure of an organ system (i.e., lasting more than 48 hours) is the prime determinant of a poor outcome. The overall mortality is approximately 2%, but it approaches 30% among patients with persistent failure of an organ system. According to another classification system, the presence of both persistent organ failure and infected pancreatic necrosis (“critical” pancreatitis) is associated with the highest mortality (see the Supplementary Appendix).26

By providing standardized definitions and descriptions of severity, as well as radiographic features, these classification systems for acute pancreatitis have value in clinical research. However, they do not provide methods for predicting severity.

**Prediction of Severity**

Knowing which patient will have severe pancreatitis could allow earlier triage to an intermediate care or intensive care unit and earlier initiation of effective therapy. Prediction of severity has been accomplished through careful observation by an experienced clinician, with symptoms,
signs, and the results of routine laboratory and radiographic testing taken into account. This process largely allows the identification of severe pancreatitis as it develops. A host of predictors, including clinical and laboratory markers and various scoring systems, have been developed to improve clinical judgment.

Clinical factors that increase the risk of complications or death among patients with acute pancreatitis include advanced age (≥60 years), numerous and severe coexisting conditions (a score of ≥2 on the Charlson comorbidity index [a weighted sum of diseases according to the codes of the International Classification of Diseases, 10th revision, with higher scores indicating a greater disease burden]), obesity (a body-mass index of >30 [calculated as the weight in kilograms divided by the square of the height in meters]), and long-term, heavy alcohol use. A variety of laboratory measures have also been studied, primarily measures of intravascular volume depletion due to third-space losses (i.e., the leakage of fluid from the intravascular spaces and into the interstitial spaces), such as hemoconcentration and azotemia, or markers of inflammation (e.g., elevated levels of C-reactive protein and interleukins 6, 8, and 10). Several of these measures have reasonable predictive value for severe acute pancreatitis. The most useful predictors are elevated blood urea nitrogen and creatinine levels and an elevated hematocrit, particularly if they do not return to the normal range during the next 24 to 48 hours (hematocrit, >44%; blood urea nitrogen level, >20 mg per deciliter [7 mmol per liter]; or creatinine level, >1.8 mg per deciliter [159 μmol per liter]), and the presence of SIRS to identify patients who are at greatest risk for severe disease and most likely to benefit from a high-intensity nursing unit.
On the basis of retrospective studies suggesting that aggressive fluid administration during the first 24 hours reduces morbidity and mortality, current guidelines provide directions for early and vigorous fluid administration. Vigorous fluid therapy is most important during the first 12 to 24 hours after the onset of symptoms and is of little value after 24 hours. Administration of a balanced crystalloid solution has been recommended at a rate of 200 to 500 ml per hour, or 5 to 10 ml per kilogram of body weight.
Feeding

Total parenteral nutrition is now known to be more expensive, riskier, and no more effective than enteral nutrition in patients with acute pancreatitis. In patients with mild acute pancreatitis who do not have organ failure or pancreatic necrosis, there is no need for complete resolution of pain or normalization of pancreatic enzyme levels before oral feeding is started. Clinical cardiopulmonary monitoring for fluid status, hourly measurement of urine output, and monitoring of the blood urea nitrogen level and hematocrit are practical ways to gauge the adequacy of fluid therapy.

The main, and not inconsequential, risk of fluid therapy is volume overload. Excessive fluid administration results in increased risks of the abdominal compartment syndrome, sepsis, need for intubation, and death. Fluid therapy needs to be tailored to the degree of intravascular volume depletion and the cardiopulmonary reserve that is available to handle the fluid. All recommendations regarding fluid resuscitation in patients with acute pancreatitis are based largely on expert opinion. Randomized trials are needed to address the type of fluid, the rate of administration, and the goals of therapy. In the interim, it seems prudent to provide the aggressive regimen of fluid therapy outlined above, as tolerated, in the first 24 hours of illness.

Antibiotic Therapy

Although the development of infected pancreatic necrosis confers a significant risk of death, well-designed trials have shown no benefit of prophylactic antibiotics. Prophylaxis with antibiotic therapy is not recommended for any type of acute pancreatitis unless infection is suspected or has been confirmed (Fig. 1). Nonetheless, many patients continue to receive prophylactic antibiotics despite guidelines to the contrary.

Endoscopic Therapy

ERCP is used primarily in patients with gallstone pancreatitis and is indicated in those who have evidence of cholangitis superimposed on gallstone pancreatitis. This procedure is also a reasonable treatment in patients with documented choledocholithiasis on imaging or findings strongly suggestive of a persistent bile duct stone (e.g., jaundice, a progressive rise in the results of liver biochemical studies, or a persistently dilated bile duct). ERCP is not beneficial in the absence of these features, in mild cases of acute gallstone pancreatitis, or as a diagnostic test before cholecystectomy. Endoscopic ultrasonography is used as a platform for minimally invasive treatment of a pancreatic pseudocyst or walled-off pancreatic necrosis (discussed below).
TREATMENT OF FLUID COLLECTIONS AND NECROSIS

Acute peripancreatic fluid collections (see the Supplementary Appendix) do not require therapy. Symptomatic pseudocysts are managed primarily with the use of endoscopic techniques, depending on local expertise.

Necrotizing pancreatitis includes pancreatic gland necrosis and peripancreatic fat necrosis. In the initial phases, the necrotic collection is a mix of semisolid and solid tissue. Over a period of 4 weeks or longer, the collection becomes more liquid and becomes encapsulated by a visible wall. At this point, the process is termed walled-off pancreatic necrosis. Sterile necrosis does not require therapy except in the rare case of a collection that obstructs a nearby viscus (e.g., duodenal, bile duct, or gastric obstruction).

The development of infection in the necrotic collection is the main indication for therapy. Such infections are rare in the first 2 weeks of the illness. The infection is usually monomicrobial and can involve gram-negative rods, enterobacter species, or gram-positive organisms, including staphylococcus. Drug-resistant organisms are increasingly prevalent. The development of fever, leukocytosis, and increasing abdominal pain suggests infection of the necrotic tissue. A CT scan may reveal evidence of air bubbles in the necrotic cavity.

Therapy begins with the initiation of broad-spectrum antibiotics that penetrate the necrotic tissue. Aspiration and culture of the collection are not required. In current practice, efforts are made to delay any invasive intervention for at least 4 weeks to allow for walling off of the necrotic collection — that is, demarcation of the boundary between necrotic and healthy tissue, softening and liquefaction of the contents, and formation of a mature wall around the collection. This delay makes drainage and débridement easier and reduces the risk of complications or death. Delayed intervention is possible in most patients whose condition remains reasonably stable, without the development of a progressive sepsis syndrome. In patients whose condition is not stable, the initial placement of a percutaneous drain in the collection is often enough to reduce sepsis and allow the 4-week delay to be continued.

Nearly 60% of patients with necrotizing pancreatitis can be treated noninvasively and will have a low risk of death. For patients in whom infected necrosis develops, a step-up approach with a delay in definitive treatment is now standard. The step-up approach consists of antibiotic administration, percutaneous drainage as needed, and after a delay of several weeks, minimally invasive débridement, if required. This approach is superior to traditional open necrosectomy with respect to the risk of major complications or death, and approximately one third of patients treated with this approach will not require débridement. A number of minimally invasive techniques (e.g., percutaneous, endoscopic, laparoscopic, and retroperitoneal approaches) are available to débride infected necrotic tissue in patients with walled-off pancreatic necrosis. A small proportion of patients with infected necrosis can be treated with antibiotics alone.

LONG-TERM CONSEQUENCES OF ACUTE PANCREATITIS

After acute pancreatitis, pancreatic exocrine and endocrine dysfunction develops in approximately 20 to 30% of patients and clear-cut chronic pancreatitis develops in one third to one half of those patients. Risk factors for the transition to recurrent attacks and chronic pancreatitis include the severity of the initial attack, the degree of pancreatic necrosis, and the cause of acute pancreatitis. In particular, long-term, heavy alcohol use as the cause and smoking as a cofactor dramatically increase the risk of a transition to chronic pancreatitis and reinforce the need for strong efforts to encourage abstinence.

PREVENTION OF RELAPSE

Cholecystectomy prevents recurrent gallstone pancreatitis. A delay of cholecystectomy for more than a few weeks places the patient at a high (up to 30%) risk for relapse. Cholecystectomy performed during the initial hospitalization for mild pancreatitis due to gallstones reduces the rate of subsequent gallstone-related complications by almost 75%, as compared with cholecystectomy performed 25 to 30 days after discharge. For patients with severe or necrotizing pancreatitis, cholecystectomy may be delayed in order to address other clinically significant conditions or provide time for the pancreatic inflammation to diminish, allowing for better operative exposure. For patients who are not considered to be candi-
dates for surgery, endoscopic biliary sphincterotomy will reduce (but not eliminate) the risk of recurrent biliary pancreatitis but may not reduce the risk of subsequent acute cholecystitis and biliary colic.64

Patients with alcohol-associated acute pancreatitis who continue to drink alcohol have a high risk of recurrent pancreatitis and, ultimately, chronic pancreatitis.2,85,66 Half of such patients have a recurrence; the risk is markedly lower for those who are abstinent.66 A structured, consistent intervention to encourage abstinence is effective at preventing relapse65 but is often not used. Interventions directed at smoking cessation are also effective preventive measures, since both alcohol and smoking are common risk factors for pancreatitis.

Implicating a specific drug as a cause of acute pancreatitis is difficult, often incorrect, and potentially dangerous if the role of another drug is overlooked.13 In the absence of any alternative causes, withdrawing an implicated medication may prevent relapse.

Tight control of hyperlipidemia can prevent a relapse of pancreatitis caused by hypertriglyceridemia.68,69 Serum triglyceride levels will fall in the absence of oral intake of food and fluids. Thus, if it is unclear whether hyperlipidemia caused the acute attack, repeated measurements of blood triglyceride levels after discharge, while the patient is on a stable oral diet, can be informative.

Primary prevention of pancreatitis is possible only in the case of pancreatitis caused by ERCP. ERCP should be avoided in patients who are not likely to benefit from it (e.g., those with suspected sphincter of Oddi dysfunction).1 Preventive therapies can be used in patients at high risk for post-ERCP pancreatitis on the basis of demographic, clinical, or procedural factors.70 Two moderately effective therapies are now available: temporary placement of pancreatic duct stents71 and pharmacologic prophylaxis with nonsteroidal antiinflammatory drugs72 (Table 1).

CONCLUSIONS

Acute pancreatitis is an increasingly common clinical problem. New approaches to fluid resuscitation, antibiotic use, nutritional support, and treatment of necrosis have changed management but have not yet been widely adopted. More effective prevention of post-ERCP pancreatitis is possible, and gallstone pancreatitis can be prevented with timely cholecystectomy. The management of acute pancreatitis should continue to improve, as new consensus definitions help to guide clinical research and, even more important, as large clinical consortia collaborate on randomized trials.

Dr. Swaroop Vege reports receiving consulting fees from CalciMedica, Takeda, Bharat Serums and Vaccines, and Teva and fees for educational activities for residents and fellows from BCH Mumbai. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

REFERENCES

15. Sadar-Azodi O, Orsini N, André-Sandberg Å, Wolk A. Abdominal and toxic adiposity and the risk of acute pancreatitis: a population-based prospective
Acute Pancreatitis: a systematic review and meta-analysis.